MRM · MEDIROM Healthcare Technologies Inc.

This 6-K filing serves as a formal notice convening MEDIROM’s annual shareholder meeting, centered on two governance actions: approval of unaudited non-consolidated financials and renewal of board leadership. The financial statement proposal reflects a statutory requirement under Japanese law due to the absence of an external auditor since FY2024—making these figures unaudited, non-consolidated, and prepared under Japanese GAAP, which materially diverges from the U.S. GAAP consolidated statements expected later in the Form 20-F. Investors should treat this disclosure as procedural rather than analytical: no financial metrics, growth rates, or performance commentary are provided. The director election introduces Akira Nojima as a new outside director, bringing specialized healthcare governance expertise, while reinforcing board continuity with four incumbents—including founder Kouji Eguchi and CFO Fumitoshi Fujiwara. All nominees hold shares, with Eguchi holding over 1.9 million common shares—the largest disclosed stake—underscoring alignment. Voting deadlines differ for ADS holders (May 21, 2026 EST) versus direct shareholders (May 28, 2026 JST), reflecting cross-border administrative complexity. No compensation details, audit qualifications, or forward-looking guidance are included.